#Japan #AI in Healthcare #Fukuoka #Medmain #Pathology Reports

Medmain Inc. Secures a Patent for Innovative AI System

Medmain Inc., headquartered in Fukuoka, Japan, has recently obtained a significant patent for an AI system aimed at improving the efficiency of creating pathology reports. The patent, numbered 7752741, focuses on a system that assists and enhances the generation of findings in pathology diagnostics.

Overview of the Patent

The core functionality of this patent revolves around a system that cross-verifies text generated by AI from pathology images with reports drafted by medical professionals. This process automatically identifies inconsistencies, typographical errors, omissions, and any diagnostic content errors. The outcome is a remarkable enhancement in the efficiency of pathologists when creating reports, leading to better diagnostic quality and a reduction in burdens faced by healthcare professionals.

Technical Features of the Patented System

The patented technology includes several innovative features designed to optimize the workflow of pathology report generation and verification:

• - Support for Verification through Generated Text Comparison: By comparing the report text created by healthcare providers with AI-generated text based on pathology image data, the system aids in detecting issues such as typos, omissions, and inconsistencies in report content.

• - Similarity-Based Checking Mechanism: This feature calculates the similarity between the two sets of report texts. Depending on the calculated similarity, healthcare professionals are prompted to review and correct discrepancies. This mechanism efficiently mitigates the human errors often encountered during the report creation and verification stages.

Need for This Innovation

Pathology diagnosis stands at the core of medical evaluation, yet challenges arise due to a shortage of specialists and increasing workloads. Medmain has been a proponent of advancing digital pathology through its cloud system, PidPort, and other AI innovations, all aimed at alleviating pressures within the medical community.

Particularly in the report generation process, the risks of human errors such as typographical mistakes or content inconsistencies pose significant threats to the quality of healthcare. The newly acquired patent addresses these risks by providing a system that simultaneously validates findings crafted by healthcare professionals against AI-generated content.

This innovative approach assists in preventing human errors while ensuring that the final judgment remains with the treating physician, thus safeguarding the quality and reliability of diagnostic results. The overall goal remains clear: to lighten the workload in medical scenarios, all while enhancing the accuracy of pathology diagnoses.

Future Directions

Moving forward, Medmain plans to integrate this patented technology into its pathology cloud system, PidPort, as well as into various digital healthcare solutions. The aim is to streamline the report generation and verification processes, significantly improving diagnostic quality. Moreover, by enhancing practicality through actual usage in healthcare settings, Medmain intends to broaden its deployment in medical institutions both domestically and internationally, emphasizing safety and reliability in pathology diagnostic support.

Patent Information

• - Patent Number: 7752741
• - Invention Title: System for Efficient Report Generation
• - Registration Date: October 2, 2025
• - Patent Holder: Medmain Inc.

Company Overview

• - Company Name: Medmain Inc.
• - Establishment Date: January 11, 2018
• - Business Details: Development, operation, and sale of medical software and cloud services.
• - CEO: Nobuhiro Iizuka
• - Locations:

- Tokyo Office: 2-10-11 Minami Aoyama, Aoyama Building 2F, Minato City, Tokyo
- Fukuoka Office: 2-4-5 Akasaka, Chuo Ward, Fukuoka City
- Silicon Valley Office: 212 Homer Ave, Palo Alto, CA 94301 USA (Medmain USA Inc.)

For more information, visit our Corporate Site or the Product Site.